ログイン

HEMATOLOGY PROGRESS EXAM PART 2

HEMATOLOGY PROGRESS EXAM PART 2
35問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    The majority of the iron in an adult is found as a constituent of: * 1/1 Hemoglobin Hemosiderin Myoglobin Transferrin

    Hemoglobin

  • 2

    An increased amount of cytoplasmic basophilia in a blood cell indicates: * 1/1 Increased cytoplasmic maturation Decreased cytoplasmic maturation Reduction in size of the cell Decreased nuclear maturation

    Decreased cytoplasmic maturation

  • 3

    Which of the following cytokines is most responsible for eosinophil differentiation and release from the bone marrow? * 0/1 IL-1 IL-2 IL-4 IL-5

    IL-5

  • 4

    After the removal of red blood cells from the circulation hemoglobin is broken down into: * 1/1 Iron, porphyrin, and amino acids Iron, heme, and globin Heme, protoporphyrin, and amino acids Heme, hemosiderin, and globin

    Iron, heme, and globin

  • 5

    Anemia secondary to uremia and chronic renal disease characteristically is: * 0/1 Microcytic, hypochromic Hemolytic Normocytic, normochromic Macrocytic

    Normocytic, normochromic

  • 6

    Which abnormal RBC morphology is associated with pyruvate kinase deficiency? * 0/1 Acanthocytes Dacryocytes Echinocytes Drepanocytes

    Echinocytes

  • 7

    Which of the following hemoglobinopathies is associated with rod shaped crystals? * 1/1 Hb S Hb C Hb SC Hb D

    Hb C

  • 8

    The Philadelphia chromosome is formed by a translocation between: * 1/1 Chromosome 22 and chromosome 9 Chromosome 21 and chromosome 9 Chromosome 21 and chromosome 6 Chromosome 22 and chromosome 6

    Chromosome 22 and chromosome 9

  • 9

    Biochemical abnormalities characteristic of polycythemia vera include: * 0/1 Increased serum B12 binding capacity Hypouricemia Hypohistaminemia Increased erythropoietin

    Increased serum B12 binding capacity

  • 10

    The disease state that presents with QUANTITATIVE platelet disorder is: * 0/1 von Willebrand disease Hemophilia A Glanzmann thrombasthenia May-Hegglin anomaly

    May-Hegglin anomaly

  • 11

    Automated methods of measuring hemoglobin cannot detect this form: * 0/1 Methemoglobin Carboxyhemoglobin Deoxyhemoglobin Sulfhemoglobin

    Sulfhemoglobin

  • 12

    In the hemoglobin solubility (dithionate) test, which type of hemoglobin causes turbidity (positive reaction)? * 1/1 Hb D Hb E Hb S Hb A

    Hb S

  • 13

    The hemoglobin variant that is seen frequently in the South East Asian population, demonstrates a microcytic blood smear, and migrates with HbC at pH 8.6 is: * 0/1 Hb Barts Hb F Hb E Hb H

    Hb E

  • 14

    Which of the following markers are usually negative in hairy cell leukemia? * 0/1 CD 5 CD 11c CD 25 CD 103

    CD 5

  • 15

    Which condition is associated with the BCR/ABL gene rearrangement and responds well to treatment with tyrosine kinase inhibitors? * 1/1 Chronic myeloid leukemia Essential thrombocytosis Chronic idiopathic myelofibrosis Polycythemia vera

    Chronic myeloid leukemia

  • 16

    Which of the following conditions is most often associated with the V617F mutation of JAK2? * 0/1 Chronic myelogenous leukemia Acute monocytic leukemia MDS with multilineage dysplasia Polycythemia vera

    Polycythemia vera

  • 17

    Vasoconstriction is caused by several regulatory molecules, which include: * 1/1 Fibrinogen and vWF ADP and EPI Thromboxane A2 and serotonin Collagen and actomyosin

    Thromboxane A2 and serotonin

  • 18

    The most potent plasminogen activator in the contact phase of coagulation is: * 0/1 Kallikrein Streptokinase HMWK Fibrinogen

    Kallikrein

  • 19

    The activation of plasminogen to plasmin resulting in the degradation of fibrin occurs by: * 1/1 PAl-1 Alpha-2 antiplasmin tPA Alpha-2 macroglobulin

    tPA

  • 20

    An inhibitor of plasmin activity is: * 0/1 tPA PAl-1 Alpha-2 antiplasmin Plasminogen

    Alpha-2 antiplasmin

  • 21

    The 2 factors that differentiate liver disease from vitamin K deficiency are: * 1/1 II and VII IX and VII VIII and IX V and VII

    V and VII

  • 22

    In patients who present with bleeding disorders caused by platelets, the most common type of bleeding is: * 1/1 Mucosal bleeding Hemarthrosis Delayed bleeding Deep hematomas

    Mucosal bleeding

  • 23

    The most common cause of bleeding in patients is: * 0/1 Qualitative platelet defect Qualitative abnormality of fibrinogen Quantitative abnormality of fibrinogen Quantitative abnormality of platelets

    Quantitative abnormality of platelets

  • 24

    Which subtype of van Willebrand disease is the most common? * 0/1 Type 1 Type 2A Type 2B Type 3

    Type 1

  • 25

    Platelet aggregation will occur with the end production of: * 1/1 Cyclooxygenase Arachidonic acid Prostacyclin Thromboxane A2

    Thromboxane A2

  • 26

    A pregnant women has routine coagulation testing performed. PT and aPTT are normal. Her fibrinogen level is elevated at 450 (reference range 150-350) due to acute phase reactants during pregnancy. The other factor that may be elevated due to this is: * 0/1 FVII FVIII FXI FXIII

    FVIII

  • 27

    Which of the following are characteristic of a factor XII deficiency? * 0/1 Negative bleeding history Negative screening test Decreased risk of thrombosis Decreased platelet count

    Negative bleeding history

  • 28

    One of the coagulation test results that correlates with mortality in patients with the SARS-CoV-2 virus was: * 1/1 PT APTT D-dimer Thrombin time

    D-dimer

  • 29

    If small blood clot exists in an anticoagulated blood specimen, which blood cell parameter will be affected the most? * 0/1 Leukocyte count Erythrocyte count Platelet count Microhematocrit

    Platelet count

  • 30

    Sometimes used in conjunction with DC: * 0/1 Electronic impedance Optical scatter Radiofrequency None of these

    Radiofrequency

  • 31

    RL flag except: * 0/1 Platelet clumps RBC fragments Giant platelets Cold agglutinins

    Cold agglutinins

  • 32

    The primary pathophysiologic mechanism of anemia associated with chronic kidney disease is: * 1/1 Inadequate production of erythropoietin Excessive hemolysis Hematopoietic stem cell mutation Toxic destruction of stem cells

    Inadequate production of erythropoietin

  • 33

    RBC with membrane folded over: * 1/1 Aplastic anemia Iron deficiency anemia Hemoglobin C, hemoglobin SC disease Sickle cell anemia, thalassemia

    Hemoglobin C, hemoglobin SC disease

  • 34

    Lazy leukocyte syndrome: * 0/1 Monocyte-macrophage series Neutrophilic series Lymphocytic series Erythrocytic series

    Neutrophilic series

  • 35

    The newer clinical instruments for measuring blood clotting are based on: 0/1 Clot elasticity Fibrin adhesion Conduction of impedance of an electrical current by fibrin Changes in optical density

    Changes in optical density

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    The majority of the iron in an adult is found as a constituent of: * 1/1 Hemoglobin Hemosiderin Myoglobin Transferrin

    Hemoglobin

  • 2

    An increased amount of cytoplasmic basophilia in a blood cell indicates: * 1/1 Increased cytoplasmic maturation Decreased cytoplasmic maturation Reduction in size of the cell Decreased nuclear maturation

    Decreased cytoplasmic maturation

  • 3

    Which of the following cytokines is most responsible for eosinophil differentiation and release from the bone marrow? * 0/1 IL-1 IL-2 IL-4 IL-5

    IL-5

  • 4

    After the removal of red blood cells from the circulation hemoglobin is broken down into: * 1/1 Iron, porphyrin, and amino acids Iron, heme, and globin Heme, protoporphyrin, and amino acids Heme, hemosiderin, and globin

    Iron, heme, and globin

  • 5

    Anemia secondary to uremia and chronic renal disease characteristically is: * 0/1 Microcytic, hypochromic Hemolytic Normocytic, normochromic Macrocytic

    Normocytic, normochromic

  • 6

    Which abnormal RBC morphology is associated with pyruvate kinase deficiency? * 0/1 Acanthocytes Dacryocytes Echinocytes Drepanocytes

    Echinocytes

  • 7

    Which of the following hemoglobinopathies is associated with rod shaped crystals? * 1/1 Hb S Hb C Hb SC Hb D

    Hb C

  • 8

    The Philadelphia chromosome is formed by a translocation between: * 1/1 Chromosome 22 and chromosome 9 Chromosome 21 and chromosome 9 Chromosome 21 and chromosome 6 Chromosome 22 and chromosome 6

    Chromosome 22 and chromosome 9

  • 9

    Biochemical abnormalities characteristic of polycythemia vera include: * 0/1 Increased serum B12 binding capacity Hypouricemia Hypohistaminemia Increased erythropoietin

    Increased serum B12 binding capacity

  • 10

    The disease state that presents with QUANTITATIVE platelet disorder is: * 0/1 von Willebrand disease Hemophilia A Glanzmann thrombasthenia May-Hegglin anomaly

    May-Hegglin anomaly

  • 11

    Automated methods of measuring hemoglobin cannot detect this form: * 0/1 Methemoglobin Carboxyhemoglobin Deoxyhemoglobin Sulfhemoglobin

    Sulfhemoglobin

  • 12

    In the hemoglobin solubility (dithionate) test, which type of hemoglobin causes turbidity (positive reaction)? * 1/1 Hb D Hb E Hb S Hb A

    Hb S

  • 13

    The hemoglobin variant that is seen frequently in the South East Asian population, demonstrates a microcytic blood smear, and migrates with HbC at pH 8.6 is: * 0/1 Hb Barts Hb F Hb E Hb H

    Hb E

  • 14

    Which of the following markers are usually negative in hairy cell leukemia? * 0/1 CD 5 CD 11c CD 25 CD 103

    CD 5

  • 15

    Which condition is associated with the BCR/ABL gene rearrangement and responds well to treatment with tyrosine kinase inhibitors? * 1/1 Chronic myeloid leukemia Essential thrombocytosis Chronic idiopathic myelofibrosis Polycythemia vera

    Chronic myeloid leukemia

  • 16

    Which of the following conditions is most often associated with the V617F mutation of JAK2? * 0/1 Chronic myelogenous leukemia Acute monocytic leukemia MDS with multilineage dysplasia Polycythemia vera

    Polycythemia vera

  • 17

    Vasoconstriction is caused by several regulatory molecules, which include: * 1/1 Fibrinogen and vWF ADP and EPI Thromboxane A2 and serotonin Collagen and actomyosin

    Thromboxane A2 and serotonin

  • 18

    The most potent plasminogen activator in the contact phase of coagulation is: * 0/1 Kallikrein Streptokinase HMWK Fibrinogen

    Kallikrein

  • 19

    The activation of plasminogen to plasmin resulting in the degradation of fibrin occurs by: * 1/1 PAl-1 Alpha-2 antiplasmin tPA Alpha-2 macroglobulin

    tPA

  • 20

    An inhibitor of plasmin activity is: * 0/1 tPA PAl-1 Alpha-2 antiplasmin Plasminogen

    Alpha-2 antiplasmin

  • 21

    The 2 factors that differentiate liver disease from vitamin K deficiency are: * 1/1 II and VII IX and VII VIII and IX V and VII

    V and VII

  • 22

    In patients who present with bleeding disorders caused by platelets, the most common type of bleeding is: * 1/1 Mucosal bleeding Hemarthrosis Delayed bleeding Deep hematomas

    Mucosal bleeding

  • 23

    The most common cause of bleeding in patients is: * 0/1 Qualitative platelet defect Qualitative abnormality of fibrinogen Quantitative abnormality of fibrinogen Quantitative abnormality of platelets

    Quantitative abnormality of platelets

  • 24

    Which subtype of van Willebrand disease is the most common? * 0/1 Type 1 Type 2A Type 2B Type 3

    Type 1

  • 25

    Platelet aggregation will occur with the end production of: * 1/1 Cyclooxygenase Arachidonic acid Prostacyclin Thromboxane A2

    Thromboxane A2

  • 26

    A pregnant women has routine coagulation testing performed. PT and aPTT are normal. Her fibrinogen level is elevated at 450 (reference range 150-350) due to acute phase reactants during pregnancy. The other factor that may be elevated due to this is: * 0/1 FVII FVIII FXI FXIII

    FVIII

  • 27

    Which of the following are characteristic of a factor XII deficiency? * 0/1 Negative bleeding history Negative screening test Decreased risk of thrombosis Decreased platelet count

    Negative bleeding history

  • 28

    One of the coagulation test results that correlates with mortality in patients with the SARS-CoV-2 virus was: * 1/1 PT APTT D-dimer Thrombin time

    D-dimer

  • 29

    If small blood clot exists in an anticoagulated blood specimen, which blood cell parameter will be affected the most? * 0/1 Leukocyte count Erythrocyte count Platelet count Microhematocrit

    Platelet count

  • 30

    Sometimes used in conjunction with DC: * 0/1 Electronic impedance Optical scatter Radiofrequency None of these

    Radiofrequency

  • 31

    RL flag except: * 0/1 Platelet clumps RBC fragments Giant platelets Cold agglutinins

    Cold agglutinins

  • 32

    The primary pathophysiologic mechanism of anemia associated with chronic kidney disease is: * 1/1 Inadequate production of erythropoietin Excessive hemolysis Hematopoietic stem cell mutation Toxic destruction of stem cells

    Inadequate production of erythropoietin

  • 33

    RBC with membrane folded over: * 1/1 Aplastic anemia Iron deficiency anemia Hemoglobin C, hemoglobin SC disease Sickle cell anemia, thalassemia

    Hemoglobin C, hemoglobin SC disease

  • 34

    Lazy leukocyte syndrome: * 0/1 Monocyte-macrophage series Neutrophilic series Lymphocytic series Erythrocytic series

    Neutrophilic series

  • 35

    The newer clinical instruments for measuring blood clotting are based on: 0/1 Clot elasticity Fibrin adhesion Conduction of impedance of an electrical current by fibrin Changes in optical density

    Changes in optical density